女性生殖器がん治療薬開発パイプラインレビュー2017

【英語タイトル】Lower Female Reproductive System Cancers Drug Development Pipeline Review, 2017

GBI Researchが出版した調査資料(GBIHC028IDB)・商品コード:GBIHC028IDB
・発行会社(調査会社):GBI Research
・発行日:2017年12月
・ページ数:129
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD3,995 ⇒換算¥451,435見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD7,990 ⇒換算¥902,870見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD11,985 ⇒換算¥1,354,305見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Lower Female Reproductive System Cancers Drug Development Pipeline Review, 2017
Summary

This report provides an overview of the Lower Female Reproductive System Cancers pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Cervical Cancer, Vaginal Cancer and Vulvar Cancer, and features dormant and discontinued projects.

Cervical intraepithelial neoplasia (CIN), also known as cervical dysplasia, is characterized by abnormal appearance of cells on the surface of the cervix. Cervical dysplasia usually occurs in women aged from 25 to 35. Most cases of cervical dysplasia are caused by human papilloma virus (HPV). Vaginal cancer is a rare cancer that causes symptoms such as watery vaginal discharge, a lump or mass in the vagina, painful urination, constipation and pelvic pain, vaginal bleeding. Finally, Vulvar cancer is another rare type of cancer. It forms in a woman’s external genitals, called the vulva.

The size of these pipelines ranges from five and six products in vulvar and vaginal cancer respectively to 163 in cervical cancer. The most prominent targets in the cervical cancer pipeline are HPV proteins there are a number of products in the pipeline targeting HPV protein E7 and HPV protein E6. Other common targets in the pipeline include vascular endothelial growth factor A and programmed cell death protein 1.

Scope

- Which companies are the most active within the pipeline for genetic ophthalmological disorder therapeutics?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in the field of genetic ophthalmological disorders?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

【レポートの目次】

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 7
2 Introduction 8
2.1 Lower Female Reproductive System Cancers Report Coverage 8
2.2 Cervical Cancer – Overview 8
2.3 Vaginal Cancer – Overview 8
2.4 Vulvar Cancer – Overview 8
3 Therapeutics Development 9
3.1 Cervical Cancer 9
3.2 Vaginal Cancer 24
3.3 Vulvar Cancer 27
4 Therapeutics Assessment 30
4.1 Cervical Cancer 30
4.2 Vaginal Cancer 42
4.3 Vulvar Cancer 48
5 Companies Involved in Therapeutics Development 54
5.1 Cervical Cancer 54
5.2 Vaginal Cancer 100
5.3 Vulvar Cancer 103
6 Dormant Projects 106
6.1 Cervical Cancer 106
6.2 Vaginal Cancer 110
6.3 Vulvar Cancer 110
7 Discontinued Products 111
7.1 Cervical Cancer 111
8 Product Development Milestones 112
8.1 Cervical Cancer 112
8.2 Vulvar Cancer 125
9 Appendix 128
9.1 Methodology 128
9.2 Coverage 128
9.3 Secondary Research 128
9.4 Primary Research 128
9.5 Expert Panel Validation 128
9.6 Contact Us 129
9.7 Disclaimer 129

1.1 List of Tables
Table 1: Number of Products under Development for Cervical Cancer 9
Table 2: Number of Products under Development by Companies, Cervical Cancer 11
Table 3: Number of Products under Development by Universities/Institutes, Cervical Cancer 15
Table 4: Products under Development by Companies, Cervical Cancer 16
Table 5: Products under Development by Universities/Institutes, Cervical Cancer 22
Table 6: Number of Products under Development for Vaginal Cancer 24
Table 7: Number of Products under Development by Companies, Vaginal Cancer 25
Table 8: Products under Development by Companies, Vaginal Cancer 26
Table 9: Number of Products under Development for Vulvar Cancer 27
Table 10: Number of Products under Development by Companies, Vulvar Cancer 28
Table 11: Products under Development by Companies, Vulvar Cancer 29
Table 12: Number of Products by Stage and Target, Cervical Cancer 31
Table 13: Number of Products by Stage and Mechanism of Action, Cervical Cancer 35
Table 14: Number of Products by Stage and Route of Administration, Cervical Cancer 39
Table 15: Number of Products by Stage and Molecule Type, Cervical Cancer 41
Table 16: Number of Products by Stage and Target, Vaginal Cancer 43
Table 17: Number of Products by Stage and Mechanism of Action, Vaginal Cancer 44
Table 18: Number of Products by Stage and Route of Administration, Vaginal Cancer 46
Table 19: Number of Products by Stage and Molecule Type, Vaginal Cancer 47
Table 20: Number of Products by Stage and Target, Vulvar Cancer 49
Table 21: Number of Products by Stage and Mechanism of Action, Vulvar Cancer 50
Table 22: Number of Products by Stage and Route of Administration, Vulvar Cancer 52
Table 23: Number of Products by Stage and Molecule Type, Vulvar Cancer 53
Table 24: Cervical Cancer – Pipeline by Abion Inc 54
Table 25: Cervical Cancer – Pipeline by Abivax SA 54
Table 26: Cervical Cancer – Pipeline by Admedus Ltd 55
Table 27: Cervical Cancer – Pipeline by Advaxis Inc 55
Table 28: Cervical Cancer – Pipeline by Advenchen Laboratories LLC 56
Table 29: Cervical Cancer – Pipeline by Agenus Inc 56
Table 30: Cervical Cancer – Pipeline by Amgen Inc 57
Table 31: Cervical Cancer – Pipeline by AntiCancer Inc 57
Table 32: Cervical Cancer – Pipeline by Antigen Express Inc 58
Table 33: Cervical Cancer – Pipeline by Arbor Vita Corp 58
Table 34: Cervical Cancer – Pipeline by ArQule Inc 59
Table 35: Cervical Cancer – Pipeline by Asana BioSciences LLC 59
Table 36: Cervical Cancer – Pipeline by AstraZeneca Plc 60
Table 37: Cervical Cancer – Pipeline by AVEO Pharmaceuticals Inc 60
Table 38: Cervical Cancer – Pipeline by Bayer AG 61
Table 39: Cervical Cancer – Pipeline by BeiGene Ltd 62
Table 40: Cervical Cancer – Pipeline by Bioleaders Corp 62
Table 41: Cervical Cancer – Pipeline by Biomics Biotechnologies Co Ltd 62
Table 42: Cervical Cancer – Pipeline by Blirt SA 63
Table 43: Cervical Cancer – Pipeline by Boehringer Ingelheim GmbH 63
Table 44: Cervical Cancer – Pipeline by Bristol-Myers Squibb Co 64
Table 45: Cervical Cancer – Pipeline by Cadila Healthcare Ltd 64
Table 46: Cervical Cancer – Pipeline by Cancer Research Technology Ltd 65
Table 47: Cervical Cancer – Pipeline by Celleron Therapeutics Ltd 65
Table 48: Cervical Cancer – Pipeline by Coherus BioSciences Inc 66
Table 49: Cervical Cancer – Pipeline by Critical Outcome Technologies Inc 66
Table 50: Cervical Cancer – Pipeline by Cytori Therapeutics Inc 67
Table 51: Cervical Cancer – Pipeline by CZ BioMed Corp 67
Table 52: Cervical Cancer – Pipeline by DelMar Pharmaceuticals Inc 68
Table 53: Cervical Cancer – Pipeline by Dr. Reddy's Laboratories Ltd 68
Table 54: Cervical Cancer – Pipeline by Eisai Co Ltd 69
Table 55: Cervical Cancer – Pipeline by Etubics Corp 69
Table 56: Cervical Cancer – Pipeline by Eureka Therapeutics Inc 70
Table 57: Cervical Cancer – Pipeline by EyeGene Inc 70
Table 58: Cervical Cancer – Pipeline by F. Hoffmann-La Roche Ltd 71
Table 59: Cervical Cancer – Pipeline by Formune SL 71
Table 60: Cervical Cancer – Pipeline by GamaMabs Pharma SA 72
Table 61: Cervical Cancer – Pipeline by Gene Techno Science Co Ltd 72
Table 62: Cervical Cancer – Pipeline by Genentech Inc 73
Table 63: Cervical Cancer – Pipeline by Genmab A/S 73
Table 64: Cervical Cancer – Pipeline by Genor BioPharma Co Ltd 74
Table 65: Cervical Cancer – Pipeline by GlaxoSmithKline Plc 74
Table 66: Cervical Cancer – Pipeline by Glycostem Therapeutics BV 75
Table 67: Cervical Cancer – Pipeline by Glycotope GmbH 75
Table 68: Cervical Cancer – Pipeline by Gradalis Inc 76
Table 69: Cervical Cancer – Pipeline by Immunomedics Inc 76
Table 70: Cervical Cancer – Pipeline by Immunovaccine Inc 77
Table 71: Cervical Cancer – Pipeline by Innate Pharma SA 77
Table 72: Cervical Cancer – Pipeline by Innovation Pharmaceuticals Inc 78
Table 73: Cervical Cancer – Pipeline by Iovance Biotherapeutics Inc 78
Table 74: Cervical Cancer – Pipeline by ISA Pharmaceuticals BV 79

【掲載企業】

Abion Inc
Abivax SA
Admedus Ltd
Advaxis Inc
Advenchen Laboratories LLC
Agenus Inc
Amgen Inc
AntiCancer Inc
Antigen Express Inc
Arbor Vita Corp
ArQule Inc
Asana BioSciences LLC
AstraZeneca Plc
AVEO Pharmaceuticals Inc
Bayer AG
BeiGene Ltd
Bioleaders Corp
Biomics Biotechnologies Co Ltd
Blirt SA
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Co
Cadila Healthcare Ltd
Cancer Research Technology Ltd
Celleron Therapeutics Ltd
Cervical Cancer
Coherus BioSciences Inc
Critical Outcome Technologies Inc
Cutanea Life Sciences Inc
Cytori Therapeutics Inc
CZ BioMed Corp
DelMar Pharmaceuticals Inc
Dr. Reddy's Laboratories Ltd
Eisai Co Ltd
Etubics Corp
Eureka Therapeutics Inc
EyeGene Inc
F. Hoffmann-La Roche Ltd
Formune SL
GamaMabs Pharma SA
Gene Techno Science Co Ltd
Genentech Inc
Genmab A/S
Genor BioPharma Co Ltd
GlaxoSmithKline Plc
Glycostem Therapeutics BV
Glycotope GmbH
Gradalis Inc
Immunomedics Inc
Immunovaccine Inc
Innate Pharma SA
Innovation Pharmaceuticals Inc
Iovance Biotherapeutics Inc
ISA Pharmaceuticals BV
Johnson & Johnson
Juno Therapeutics Inc
Kaketsuken
Karyopharm Therapeutics Inc
Kite Pharma Inc
LondonPharma Ltd
Mabion SA
MedImmune LLC
Merck & Co Inc
Merck KGaA
Mycenax Biotech Inc
Nektar Therapeutics
NeoImmuneTech Inc
Ology Bioservices Inc
Oncobiologics Inc
Ono Pharmaceutical Co Ltd
Oryx GmbH & Co KG
PDS Biotechnology Corp
Pfizer Inc
Pharma Mar SA
Psicofarma SA de CV
Puma Biotechnology Inc
Regeneron Pharmaceuticals Inc
Rexahn Pharmaceuticals Inc
Richter Gedeon Nyrt
Samyang Holdings Corp
Sanofi
Seattle Genetics Inc
Selecta Biosciences Inc
Shantha Biotechnics Pvt Ltd
Sirnaomics Inc
Sun Pharma Advanced Research Company Ltd
Taiwan Liposome Company Ltd
Tessa Therapeutics Pte Ltd
Theralase Technologies Inc
Theravectys SA
THEVAX Genetics Vaccine USA Inc
UbiVac LLC
Vectorite Biomedica Inc
VLPbio
Wellstat Biologics Corp
Zeria Pharmaceutical Co Ltd

★調査レポート[女性生殖器がん治療薬開発パイプラインレビュー2017] (コード:GBIHC028IDB)販売に関する免責事項を必ずご確認ください。
★調査レポート[女性生殖器がん治療薬開発パイプラインレビュー2017]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆